Guggenheim Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $70

Benzinga Newsdesk www.benzinga.com Positive 59.9%

Neg 0% Neu 0% Pos 59.9%

Guggenheim analyst Yatin Suneja initiates coverage on Korsana Biosciences (NASDAQ:KRSA) with a Buy rating and announces Price Target of $70.